NIH Finds Non-Chemo Drug Combo Induces Lasting Remission in DLBCL Patients

NIH Main, Maryland/iStock, Grandbrothers

Pictured: The National Institutes of Health’s main building in Maryland/iStock, Grandbrothers

Researchers from the National Institutes of Health have identified a novel, non-chemotherapy combination regimen for treating relapsed diffuse large B-cell lymphoma, reporting full remission for some patients no longer responding to standard treatments.

Detailing their findings Wednesday in The New England Journal of Medicine, the NIH scientists combined five common anti-cancer agents—AbbVie and Genentech’s Vencelxta (venetoclax), Johnson & Johnson’s Imbruvica (ibrutinib), Genentech’s Gazyva (obinutuzumab), Bristol Myers Squibb’s Revlimid (lenalidomide) and the corticosteroid prednisone.

The treatment combo, dubbed ViPOR, was tested in a Phase Ib/II study that included 50 patients with diffuse large B-cell lymphoma (DLBCL). Results showed that the investigational regimen “substantially” shrank tumors in 28 of 48 evaluable patients, according to the NIH. This corresponded to a 54% objective response rate.

Overall, 18 patients saw their tumors completely…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks